Temozolomide Capsules, 250 mg, 5-count bottles, Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA, NDC 0378-5265-98.
Published February 1, 2017 · Recall initiated: December 20, 2016
Summary
FDA records drug Class II recall D-0444-2017, published February 1, 2017 and initiated December 20, 2016. Recalling firm: Mylan LLC.; Status: Terminated; Reported quantity: 588 bottles; Lot: LOT #: 2006912, Exp 02/18. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.
What to do
Voluntary: Firm initiated
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Mylan LLC.
- Distributor
- Nationwide in the USA
- Lot
- LOT #: 2006912, Exp 02/18
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDATemozolomide Capsules, 100 mg, packaged in a) 5-count bottles (NDC 0378-5262-98), b) 14-count bottles (NDCFebruary 1, 2017
- FDATemozolomide Capsules, 180 mg, packaged in a) 5-count bottles (NDC 0378-5264-98), b) 14-count bottles (NDCFebruary 1, 2017
- FDATemozolomide Capsules, 140 mg, packaged in a) 5-count bottles (NDC 0378-5263-98), b) 14-count bottles (NDCFebruary 1, 2017
- FDAbuPROPion Hydrochloride Extended-release Tablets, USP (SR), 150 mg, a) 60 (NDC 47335-737-86), b) 100 (NDCFebruary 1, 2017
- FDAbuPROPion Hydrochloride Extended-release Tablets, USP (SR), 200 mg, 60 count bottles, Rx only, Distributed by:February 1, 2017
- FDAMylan, Tacrolimus Capsules 0.5 mg, 100 count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505December 5, 2012
Questions about this recall
Was Temozolomide Capsules, 250 mg, 5-count bottles, Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA, NDC 0378-5265-98. recalled?
Yes. FDA published recall D-0444-2017 on February 1, 2017. Reported hazard: Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.
What should I do if I have this product?
Voluntary: Firm initiated